Shiftbio
Seoul, KR· latest recorded location
SHIFTBIO is named on 2 US grants and 5 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 2
- Published applications
- 5
- Inventors
- 17
- Granted in 2026 so far
- 0
- Most recent grant
- 13 May 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2023 | 0 | 1 |
| 2024 | 1 | 3 |
| 2025 | 1 | 0 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 7 documents
Recent patents
- Recombinant plasma membrane-based vesicle, for treating cancer13 May 2025US 12,295,978 B2
- Exosome-based anticancer agent9 Apr 2024US 11,952,412 B2
- Novel recombinant exosome and use thereof3 Sep 2026US 2026/0256875 A1
- Novel exosome-based anticancer agent27 Jun 2024US 2024/0209063 A1
- Method for inducing resolutive macrophage and uses therof15 Feb 2024US 2024/0050523 A1
- Method for treating cancer and inflammatory diseases using stem cell- derived extracellular vesicles comprising sirp25 Jan 2024US 2024/0024418 A1
- Surface-engineered extracellular vesicles and therapeutic uses thereof30 Nov 2023US 2023/0381226 A1
Most cited
By later US patents
None of its patents has been cited by a later US patent yet.